PnuBioVax (PBV) vaccine to prevent SPN3 carriage in a controlled human infection model (CHIM)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410920145275

Enrollment

366

Registered

2024-10-28

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumococcal carriage

Interventions

Pnu Bio Vax

PCV13

Normal saline placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adults Aged 18-50 yrs

Exclusion criteria

Exclusion criteria: Pregnant Any intercurrent illness Previous pneumococcal vaccination Previous pneumococcal CHIM

Design outcomes

Primary

Measure	Time frame
Experimental human pneumococcal carriage demonstrated by culture of nasal wash or swab.	—

Secondary

Measure	Time frame
Immunological response to PBV or PCV13 compared to placebo;Immunological response to inoculation with SPN3	—

Countries

Malawi

Contacts

Public ContactNeema Toto

Programme Coordinator

ntoto@mlw.mw+265992892182

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026